OM vs. KIDS, CATX, SIBN, IRMD, BVS, ZJYL, TMCI, NNOX, AXGN, and SGHT
Should you be buying Outset Medical stock or one of its competitors? The main competitors of Outset Medical include OrthoPediatrics (KIDS), Perspective Therapeutics (CATX), SI-BONE (SIBN), Iradimed (IRMD), Bioventus (BVS), Jin Medical International (ZJYL), Treace Medical Concepts (TMCI), Nano-X Imaging (NNOX), AxoGen (AXGN), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.
OrthoPediatrics (NASDAQ:KIDS) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability.
OrthoPediatrics received 283 more outperform votes than Outset Medical when rated by MarketBeat users. Likewise, 64.42% of users gave OrthoPediatrics an outperform vote while only 38.98% of users gave Outset Medical an outperform vote.
OrthoPediatrics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Outset Medical has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500.
In the previous week, Outset Medical had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 4 mentions for Outset Medical and 3 mentions for OrthoPediatrics. Outset Medical's average media sentiment score of 0.94 beat OrthoPediatrics' score of 0.69 indicating that OrthoPediatrics is being referred to more favorably in the media.
OrthoPediatrics presently has a consensus target price of $44.75, suggesting a potential upside of 37.27%. Outset Medical has a consensus target price of $5.42, suggesting a potential upside of 44.83%. Given OrthoPediatrics' higher possible upside, analysts clearly believe Outset Medical is more favorable than OrthoPediatrics.
OrthoPediatrics has higher revenue and earnings than Outset Medical. OrthoPediatrics is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.
69.1% of OrthoPediatrics shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by company insiders. Comparatively, 3.5% of Outset Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
OrthoPediatrics has a net margin of -13.58% compared to OrthoPediatrics' net margin of -134.93%. Outset Medical's return on equity of -5.12% beat OrthoPediatrics' return on equity.
Summary
OrthoPediatrics beats Outset Medical on 13 of the 18 factors compared between the two stocks.
Get Outset Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outset Medical Competitors List
Related Companies and Tools
Free OM Stock Alerts